Effects of an intensive short-term diet and exercise intervention: comparison between normal-weight and obese

Christian K Roberts1, Ali Izadpanah, Siddhartha S Angadi

  • 1Exercise and Metabolic Disease Laboratory, Translational Section, School of Nursing, University of California Los Angeles, Los Angeles, California 90095-6918, USA. croberts@ucla.edu

Insights

A short-term lifestyle intervention improved metabolic health in both normal-weight and overweight children. These findings suggest that diet and inactivity, not just obesity, drive metabolic changes, offering new management strategies.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Health
  • Lifestyle Medicine

Background:

  • Current lifestyle interventions focus on weight loss for obesity-related changes.
  • The impact of such programs on normal-weight versus overweight/obese children is not well understood.

Purpose of the Study:

  • To investigate if a short-term lifestyle intervention program yields different results in normal-weight compared to overweight/obese children.
  • To assess changes in metabolic risk factors, including lipids, glucose homeostasis, inflammatory cytokines, and adipokines.

Main Methods:

  • A 2-week intensive lifestyle intervention program was implemented.
  • Participants included 19 overweight/obese children and 14 normal-weight children.
  • Diet consisted of ad libitum high-fiber, low-fat intake with daily exercise (2-2.5 hours).
  • Fasting serum samples were analyzed pre- and post-intervention.

Main Results:

  • Only the overweight/obese group experienced weight loss (3.9%), remaining overweight.
  • Both groups showed significant reductions in insulin, HOMA-IR, leptin, amylin, resistin, PAI-1, IL-6, IL-8, and TNFα.
  • No correlation was found between weight change and phenotypic improvements.

Conclusions:

  • A short-term, intensive lifestyle intervention effectively improves metabolic risk factors in both normal-weight and overweight/obese children.
  • Obesity itself may not be the sole driver of metabolic abnormalities; dietary intake and physical inactivity play crucial roles.
  • These findings support weight loss-independent management of cardiometabolic risk in pediatric populations.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...